EVLO Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EST
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.02 - $6.83
Previous CloseN/A
Volume66.00
Average Volume (3M)0.00
Market Cap
$19.00
Enterprise Value$84.83
Total Cash (Recent Filing)$17.26M
Total Debt (Recent Filing)$33.95M
Price to Earnings (P/E)―
Beta-25.09
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding18,982,838
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-28.11
Price to Sales (P/S)0.00
P/FCF Ratio-1.38
Enterprise Value/Market Cap4.46
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Evelo Biosciences News
EVLO FAQ
What was Evelo Biosciences Inc’s price range in the past 12 months?
Evelo Biosciences Inc lowest stock price was $0.02 and its highest was $6.83 in the past 12 months.
What is Evelo Biosciences Inc’s market cap?
Evelo Biosciences Inc’s market cap is $19.00.
When is Evelo Biosciences Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Evelo Biosciences Inc’s earnings last quarter?
Currently, no data Available
Is Evelo Biosciences Inc overvalued?
According to Wall Street analysts Evelo Biosciences Inc’s price is currently Overvalued.
Does Evelo Biosciences Inc pay dividends?
Evelo Biosciences Inc does not currently pay dividends.
What is Evelo Biosciences Inc’s EPS estimate?
Evelo Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evelo Biosciences Inc have?
Evelo Biosciences Inc has 18,982,838 shares outstanding.
What happened to Evelo Biosciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evelo Biosciences Inc?
Currently, no hedge funds are holding shares in EVLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evelo Biosciences Inc
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.
Nuwellis
―
Scinai Immunotherapeutics
―
PainReform
―
Dermata Therapeutics
―
Virax Biolabs Group Ltd. Class A
―
Ownership Overview
―
Insiders
―
Mutual Funds
51.91% Other Institutional Investors
48.09% Public Companies and
Individual Investors